Eslicarbazepine in adults with focal-onset seizures

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, multicenter observational study follows adults with focal-onset epilepsy to observe the real-world effectiveness, safety, tolerability, and impact on quality of life of eslicarbazepine. Treatment decisions, including starting or switching to eslicarbazepine, are made by treating physicians per standard clinical practice. Participants are assessed at baseline, day 7, and at 3 months, with data collected on seizures, tolerability, adverse events, and quality of life using QOLIE-10-P. The study does not assign treatments and aims to reflect routine use in diverse clinical settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (aged at least 18 years) with diagnosed partial-onset seizures.
* Newly diagnosed (treatment-naïve) or previously treated with Carbamazepine or Oxcarbazepine and inadequately controlled or intolerant.
* Patient or Legal Representative is willing and able to provide informed consent, or, in the absence of a legal representative, an Independent Healthcare Professional provides authorization for patient enrolment.

Exclusion Criteria:

* Any hypersensitivity to Eslicarbazepine.
* Female patients who are pregnant or lactating.
* Patients who have a contraindication to the medicine or any component of prescribed therapy.

Where it's running

• Mayo Hospital Lahore
  Lahore, Punjab Province, Pakistan Recruiting

Study contacts

• Study coordinator: Safia Assistant Professor Neurology, FCPS Neurology, PhD Scholar
• Email: safiabano@kemu.edu.pk
• Phone: +92-301-4154276

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating SPN-817 for adults with focal onset seizures

  This study is testing a new medication called SPN-817 to see if it can help adults with focal onset seizures who haven't found relief from other treatments.

  Recruiting at 60 sites Phase 2 Supernus Pharmaceuticals, Inc. · Phoenix, Arizona and 62 other locations · NCT06798896

• Evaluating XEN1101 for Focal-Onset Seizures

  This study is testing if a new medication called XEN1101 can help people with focal-onset seizures when added to their current seizure treatments.

  Recruiting at 63 sites Phase 3 Xenon Pharmaceuticals Inc. · Little Rock, Arkansas and 102 other locations · NCT05716100

• Evaluating the impact of cenobamate on healthcare resource use in epilepsy patients

  This study looks at how using cenobamate affects the healthcare needs of people with uncontrolled focal-onset seizures.

  Recruiting at 6 sites Aziende Chimiche Riunite Angelini Francesco S.p.A · Freiburg im Breisgau, Germany and 9 other locations · NCT06922175

• Evaluating a new ultrasound treatment for drug-resistant epilepsy

  This study is testing a new ultrasound treatment for people with drug-resistant epilepsy to see if it can help reduce their seizures and improve their quality of life.

  Recruiting NaviFUS Corporation · Taipei · NCT06492720

• Low-intensity focused ultrasound treatment for drug-resistant epilepsy

  This study is testing if low-intensity focused ultrasound can help people with drug-resistant temporal lobe epilepsy have fewer seizures while they continue taking their regular medications.

  Recruiting at 3 sites Phase 1/2 NaviFUS Corporation · Palo Alto, California and 2 other locations · NCT06388707

• Cannabidiol oral solution for treating focal-onset seizures

  We will test whether a cannabidiol oral solution (CBD-OS) can reduce focal-onset seizures in people aged 12 to 75 who are taking 1–4 stable antiseizure medications.

  Recruiting at 21 sites Phase 1 Jazz Pharmaceuticals · Phoenix, Arizona and 23 other locations · NCT07233239

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.